Section Arrow
Quote
LYRA.NASDAQ
- Lyra Therapeutics
Quotes are at least 15-min delayed:2024/05/19 06:06 EDT
Last
 0.383
+0.0154 (+4.19%)
Day High 
0.4185 
Prev. Close
0.3676 
1-M High
5.77 
Volume 
5.86M 
Bid
0.383
Ask
0.388
Day Low
0.356 
Open
0.3707 
1-M Low
0.3467 
Market Cap 
22.41M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 0.76 
20-SMA 2.9 
50-SMA 4.59 
52-W High 6.79 
52-W Low 0.3467 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.17/-1.23
Enterprise Value
43.86M
Balance Sheet
Book Value Per Share
1.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.56M
Operating Revenue Per Share
0.02
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NBYNovaBay Pharmaceuticals0.1186-0.0014-1.17%-- 
SCPXScorpius Holdings0.1035+0.0034+3.40%-- 
JAGXJaguar Health0.2585-0.0282-9.84%-- 
DNAGinkgo Bioworks Holdings0.8056-0.0334-3.98%-- 
ONCOOnconetix0.156+0.015+10.64%-- 
Quotes are at least 15-min delayed：2024/05/19 06:06 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.